Sciatica Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 9.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Sciatica Market Analysis
The Sciatica Market is expected to register a CAGR of 9.5% during the forecast period.
Certain factors driving market growth include the high recurrence rate of sciatica in patients, which impacts the market positively as patients try new interventions. Sciatica is likely to recur if the spinal disc that contributed to sciatica is severely damaged. The more damaged the disc, the more likely it is to re-herniate and cause sciatica again.
For instance, in a study published in the National Library of Medicine in August 2022, patients with chronic pain (more than six months) had a poorer outcome following surgery than patients with acute pain (less than six months). Some studies reported a cure rate of more than 75%, but other studies reported cure rates of less than 50%. There are several newer orthopedic procedures to manage sciatica, and these procedures have success rates of 70% and above in the short term. Therefore, with the advances in orthopedic procedures, the market studied is expected to grow over the coming years.
Several environmental and inherent factors thought to influence the development of sciatica have been studied, including gender, body habitus, parity, age, genetic factors, occupation, and environmental factors. For instance, according to Complete Orthopedics in July 2023, sciatica, identified as low back pain with leg pain extending below the knee, impacted 9.9% to 25% of the general population annually in the United States. Thus, the high annual prevalence rates for sciatica in developed nations are increasing demand for its treatment, thereby contributing to market growth.
However, the lack of proper diagnostic tests and the availability of off-label medication are projected to restrain market growth over the forecast period.
Sciatica Market Trends
Non-steroidal Anti-inflammatory Drug Segment Expected to Witness Strong Growth Over the Forecast Period
The main anti-inflammatory and analgesic effects of NSAIDs are based on the suppression of the cyclooxygenase (COX)1 and COX2 enzymes. By blocking the COX enzymes, vasodilation is reduced and inflammation is relieved. Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed drugs for the treatment of sciatica. The products are getting approvals, creating further lucrative opportunities in the market.
For instance, according to a study published in the BioMed Central (BMC) Journal in June 2022, NSAIDs, frequently utilized for sciatica treatment, were recommended by 80% of surveyed US physicians for the initial management of the disease. Therefore, the widespread adoption of NSAIDs for managing sciatica treatment is anticipated to foster the segment’s growth over the forecast period.
Painkillers and anti-inflammatory medicines are the most effective and most numerous drugs on the market. Antirheumatics (painkillers) are commonly used to treat pain, fever, muscle pain, and other musculoskeletal disorders. Doctors recommend low-dose medications, such as Ibuprofen or Tylenol, that can be purchased over the counter. Over-the-counter NSAIDs are meant to provide pain relief. Prescription NSAIDs may be necessary for pain relief if over-the-counter drugs are ineffective. Therefore, with the prevalence of NSAIDs in coping with sciatica, the segment is expected to grow significantly in the forecast period.
North America Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant share of the global sciatica market due to the rise in the geriatric population and the increasing prevalence of lower back pain in this region. According to a study published by the Cureus Journal in May 2023, up to 40% of patients who undergo lumbar microdiscectomy for sciatica report chronic post-surgical pain. This condition significantly impacts disability rates and productivity levels in the United States. Therefore, the US sciatica market is being driven by more orthopedic procedures for sciatica due to greater healthcare penetration.
Further, the region's increasing geriatric population is expected to significantly impact the growth of the market studied, as the older population is more prone to pain and other musculoskeletal disorders. For instance, according to the 2023 report of the United States Census Bureau, more than 17.5% of the US population aged 65 years and above lived in the country during 2023. Since older adults are more prone to developing sciatica, the market studied is expected to grow further due to the more significant percentage of the senior population.
Moreover, high expenditures on healthcare that increase the infrastructure facilities and rising awareness about the disease are further fueling the growth of the regional market. For instance, according to the Centers for Medicare & Medicaid Services, in December 2023, healthcare expenditures in the United States rose by 4.1%, reaching USD 4.5 trillion, or USD 13,493 per person in 2022, constituting 17.3% of the nation's GDP. Therefore, the North American region is expected to hold a significant share of the global sciatica market over the forecast period due to the above factors, such as the high number of geriatric patients, surgeries, and extensive healthcare expenditure in the region.
Sciatica Industry Overview
The sciatica market is fragmented, competitive in nature, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that are currently operating in the market include Sorrento Therapeutics, SpineThera, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics, Seikagaku Corporation, and Kolon Life Science.
Sciatica Market Leaders
-
Sorrento Therapeutics
-
Eliem Therapeutics
-
Scilex Holding
-
Sinfonia Biotherapeutics
-
Vita Science
*Disclaimer: Major Players sorted in no particular order
Sciatica Market News
- June 2024: Scilex Holding Company's SP-102, also known as SEMDEXA, showed promising results in treating Lumbosacral Radicular Pain, commonly known as sciatica. In its Phase 3 trial, the treatment not only met its primary endpoints but also achieved success in key secondary measures. Patients administered with SP-102 (SEMDEXA) experienced a notable decrease in pain intensity lasting more than a month. Additionally, they exhibited statistically significant and clinically relevant enhancements in their disability index scores. Importantly, these improvements were attained with a safety profile on par with the placebo.
- February 2024: Pacira BioSciences Inc. unveiled its pivotal Phase 3 study in the Journal of Clinical Anesthesia, showcasing the safety and efficacy of EXPAREL (bupivacaine liposome injectable suspension). The study focused on its application as a single-dose sciatic nerve block in the popliteal fossa for patients undergoing bunionectomy. Notably, the results underscored EXPAREL's superior performance in pain management and opioid reduction over a 96-hour period, outshining bupivacaine HCl. These pivotal findings were crucial in securing FDA approval for this specific application.
Sciatica Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Public Awareness and High Survival Rate of Sciatica
4.2.2 Risk Factors and Increasing Elderly Population
4.3 Market Restraints
4.3.1 No Single or Definitive Diagnostic Criteria Available
4.3.2 Presence of Several Off-label Drugs and Physical Therapy in the Market
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 Acute Sciatica
5.1.2 Chronic Sciatica
5.1.3 Other Types
5.2 By Pharmacological Therapies
5.2.1 Non-steroidal Anti-inflammatory Drug (NSAIDs)
5.2.2 Steroids
5.2.3 Antidepressants
5.2.4 Painkillers
5.2.5 Other Pharmacological Therapies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sorrento Therapeutics
6.1.2 SpineThera
6.1.3 Eliem Therapeutics
6.1.4 Scilex Holding
6.1.5 Sinfonia Biotherapeutics
6.1.6 Seikagaku Corporation
6.1.7 Kolon Life Science
6.1.8 Vita Sciences
6.1.9 Aurobindo Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Sciatica Industry Segmentation
As per the scope of this report, sciatica refers to pain that radiates along the path of the sciatic nerve, which branches from the lower back through the hips and buttocks and down each leg. Typically, sciatica affects only one side of the body.
The sciatica market is segmented by type, pharmacological therapies, and geography. By type, the market is segmented into acute sciatica, chronic sciatica, and other types. By pharmacological therapies, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), steroids, antidepressants, painkillers, and other pharmacological therapies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size in value terms (USD) for all the abovementioned segments.
| By Type | |
| Acute Sciatica | |
| Chronic Sciatica | |
| Other Types |
| By Pharmacological Therapies | |
| Non-steroidal Anti-inflammatory Drug (NSAIDs) | |
| Steroids | |
| Antidepressants | |
| Painkillers | |
| Other Pharmacological Therapies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Sciatica Market Research FAQs
What is the current Sciatica Market size?
The Sciatica Market is projected to register a CAGR of 9.5% during the forecast period (2024-2029)
Who are the key players in Sciatica Market?
Sorrento Therapeutics, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics and Vita Science are the major companies operating in the Sciatica Market.
Which is the fastest growing region in Sciatica Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Sciatica Market?
In 2024, the North America accounts for the largest market share in Sciatica Market.
What years does this Sciatica Market cover?
The report covers the Sciatica Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Sciatica Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Sciatica Industry Report
Statistics for the 2023 Sciatica market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Sciatica analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
